{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:11:04Z","timestamp":1778659864161,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04766-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:39:07Z","timestamp":1775122747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atopic dermatitis and ocular surface disorders: a United States claims-based cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"given":"Penny","family":"Asbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esen K.","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lubwama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Sierka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4766_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40257-019-00455-5","volume":"20","author":"KM Beck","year":"2019","unstructured":"Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part I: associated ocular diseases. Am J Clin Dermatol. 2019;20:797\u2013805.","journal-title":"Am J Clin Dermatol"},{"key":"4766_CR2","doi-asserted-by":"crossref","unstructured":"Thyssen JP, Heegaard S, Ivert L, et al. Management of ocular manifestations of atopic dermatitis: a consensus meeting using a modified Delphi process. Acta Derm Venereol. 2020;100:adv00264.","DOI":"10.2340\/00015555-3629"},{"key":"4766_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jdv.17832","volume":"36","author":"ATM R\u00f8nnstad","year":"2022","unstructured":"R\u00f8nnstad ATM, Hansen PM, Halling AS, et al. Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey. J Eur Acad Dermatol Venereol. 2022;36:592\u2013601.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4766_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","volume":"77","author":"JP Thyssen","year":"2017","unstructured":"Thyssen JP, Toft PB, Halling-Overgaard A-S, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77:280\u20136.e1.","journal-title":"J Am Acad Dermatol"},{"key":"4766_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/cea.14127","volume":"52","author":"RE Achten","year":"2022","unstructured":"Achten RE, Bakker DS, van Luijk CM, et al. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients. Clin Exp Allergy. 2022;52:801\u201305.","journal-title":"Clin Exp Allergy"},{"key":"4766_CR6","first-page":"778","volume":"13","author":"D-C Suh","year":"2007","unstructured":"Suh D-C, Sung J, Gause D, Raut M, Huang J, Choi I-S. Economic burden of atopic manifestations in patients with atopic dermatitis-analysis of administrative claims. J Manag Care Pharm. 2007;13:778\u201389.","journal-title":"J Manag Care Pharm"},{"key":"4766_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","volume":"137","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137:18\u201325.","journal-title":"The J Invest Dermatol"},{"key":"4766_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1080\/09540105.2020.1747406","volume":"31","author":"J \u010celakovsk\u00e1","year":"2020","unstructured":"\u010celakovsk\u00e1 J, Buka\u010d J, Va\u0148kov\u00e1 R, Krcmova I, Krejsek J, Andr\u00fds C. Sensitisation to molecular components in patients with atopic dermatitis, relation to asthma bronchiale and allergic rhinitis. Food Agric Immunol. 2020;31:600\u201329.","journal-title":"Food Agric Immunol"},{"key":"4766_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/all.12268","volume":"69","author":"SC Dharmage","year":"2014","unstructured":"Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69:17\u201327.","journal-title":"Allergy"},{"key":"4766_CR10","first-page":"6","volume":"77","author":"TS Gan","year":"2022","unstructured":"Gan TS, Rizal AJ, Salim NL, Lau LL, Voo SYM. Ocular co-morbidities in patients with atopic dermatitis - a cross-sectional study from a tertiary referral hospital, Malaysia. Med J Malaysia. 2022;77:6\u201311.","journal-title":"Med J Malaysia"},{"key":"4766_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s13555-020-00456-x","volume":"10","author":"J Weyne","year":"2020","unstructured":"Weyne J, Blauvelt A, de Bruin-Weller M, et al. Patient-reported ocular disorders and symptoms in adults with moderate-to-severe atopic dermatitis: screening and baseline survey data from a clinical trial. Dermatol Ther (Heidelb). 2020;10:1415\u201321.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4766_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/1346-8138.14947","volume":"46","author":"A Igarashi","year":"2019","unstructured":"Igarashi A, Fujita H, Arima K, et al. Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: a retrospective claims database analysis. J Dermatol. 2019;46:652\u201361.","journal-title":"J Dermatol"},{"key":"4766_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/09546634.2019.1659480","volume":"32","author":"KK Wu","year":"2021","unstructured":"Wu KK, Borba AJ, Deng PH, Armstrong AW. Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States. J Dermatolog Treat. 2021;32:455\u201359.","journal-title":"J Dermatolog Treat"},{"key":"4766_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","volume":"85","author":"NH Ravn","year":"2021","unstructured":"Ravn NH, Ahmadzay ZF, Christensen TA, et al. Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systemic review and meta-analysis. J Am Acad Dermatol. 2021;85:453\u201361.","journal-title":"J Am Acad Dermatol"},{"key":"4766_CR15","doi-asserted-by":"publisher","unstructured":"Zhou W, Cai J, Li Z, Lin Y. Association of atopic dermatitis with conjunctivitis and other ocular surface diseases: a bidirectional two-sample Mendelian randomization study. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19048. [Online ahead of print].","DOI":"10.1111\/jdv.19048"},{"key":"4766_CR16","first-page":"189","volume":"104","author":"JI Hsu","year":"2019","unstructured":"Hsu JI, Pflugfelder SC, Kim SJ. Ocular complications of atopic dermatitis. Cutis. 2019;104:189\u201393.","journal-title":"Cutis"},{"key":"4766_CR17","doi-asserted-by":"publisher","unstructured":"Chomistek AK, Franklin JM, Sobel R, et al. Development and validation of a claims-based algorithm for moderate-to-severe atopic dermatitis using U.S. real-world data. Br J Dermatol. 2023;188(Suppl. 2). https:\/\/doi.org\/10.1093\/bjd\/ljac140.041","DOI":"10.1093\/bjd\/ljac140.041"},{"key":"4766_CR18","doi-asserted-by":"publisher","unstructured":"van der Rijst LP, Veldhuis N, van der Kamp S, et al. Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis. Pediatr Allergy Immunol. 2025;36(2):e70040. https:\/\/doi.org\/10.1111\/pai.70040","DOI":"10.1111\/pai.70040"},{"key":"4766_CR19","first-page":"8","volume":"66","author":"A Iordache","year":"2022","unstructured":"Iordache A, Boruga M, Musat O, Jipa DA, T\u0103taru CP, Mu\u0219at GC. Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis) - review. Rom J Ophthalmol. 2022;66:8\u201312.","journal-title":"Rom J Ophthalmol"},{"key":"4766_CR20","doi-asserted-by":"publisher","first-page":"220202","DOI":"10.1183\/16000617.0202-2022","volume":"32","author":"P Rogliani","year":"2023","unstructured":"Rogliani P, Laitano R, Ora J, Beasley R, Calzetta L. Strength of association between comorbidities and asthma: a meta-analysis. Eur Respir Rev. 2023;32:220202.","journal-title":"Eur Respir Rev"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04766-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04766-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04766-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:33:45Z","timestamp":1778657625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04766-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4766"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04766-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human participants were included in this study. This was a review of de-identified administrative claims data. Informed consent was not obtained. Due to the nature of the study, Institutional Review Board\/Ethics Committee approval was not required. No animal subjects were included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PA is a consultant for Regeneron Pharmaceuticals Inc.; and has received research grants from UTHSC (The University of Tennessee Health Science Center). EKA has no relevant disclosures. JFM is a consultant and\/or investigator for AbbVie, Amgen, Biogen, Boehringer Ingelheim, BMS, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Sun Pharma, and UCB. JPT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Eli Lilly, LEO Pharma, OM Pharma, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and UNION Therapeutics; is a speaker for AbbVie, Almirall, Eli Lilly, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi; has received research grants from Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi; and is a part-time employee of LEO Pharma, since May 1, 2023. AM and MA are employees and shareholders of Regeneron Pharmaceuticals Inc. RL and DS are employees of Sanofi and may hold stock and\/or stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}